Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 449

1.

Real-Time Rain Rate Evaluation via Satellite Downlink Signal Attenuation Measurement.

Giannetti F, Reggiannini R, Moretti M, Adirosi E, Baldini L, Facheris L, Antonini A, Melani S, Bacci G, Petrolino A, Vaccaro A.

Sensors (Basel). 2017 Aug 12;17(8). pii: E1864. doi: 10.3390/s17081864.

2.

Understanding and Treating Pain Syndromes in Parkinson's Disease.

Gandolfi M, Geroin C, Antonini A, Smania N, Tinazzi M.

Int Rev Neurobiol. 2017;134:827-858. doi: 10.1016/bs.irn.2017.05.013. Epub 2017 Jul 3.

PMID:
28805585
3.

Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions.

Biundo R, Fiorenzato E, Antonini A.

Int Rev Neurobiol. 2017;133:389-415. doi: 10.1016/bs.irn.2017.05.031. Epub 2017 Jul 13.

PMID:
28802926
4.

Cognitive decline in Parkinson's disease: the complex picture.

Biundo R, Weis L, Antonini A.

NPJ Parkinsons Dis. 2016 Sep 1;2:16018. doi: 10.1038/npjparkd.2016.18. eCollection 2016. Review.

5.

PD_Manager: an mHealth platform for Parkinson's disease patient management.

Tsiouris KM, Gatsios D, Rigas G, Miljkovic D, Koroušić Seljak B, Bohanec M, Arredondo MT, Antonini A, Konitsiotis S, Koutsouris DD, Fotiadis DI.

Healthc Technol Lett. 2017 May 23;4(3):102-108. doi: 10.1049/htl.2017.0007. eCollection 2017 Jun.

6.

Cognitive impairment in multiple system atrophy.

Fiorenzato E, Antonini A, Wenning G, Biundo R.

Mov Disord. 2017 Jul 3. doi: 10.1002/mds.27085. [Epub ahead of print] Review. No abstract available.

PMID:
28671311
7.

Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.

Fabbri M, Reimão S, Carvalho M, Nunes RG, Abreu D, Guedes LC, Bouça R, Lobo PP, Godinho C, Coelho M, Gonçalves NC, Rosa MM, Antonini A, Ferreira JJ.

J Parkinsons Dis. 2017;7(3):491-501. doi: 10.3233/JPD-171135.

PMID:
28671143
8.

A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement.

de Roos P, Bloem BR, Kelley TA, Antonini A, Dodel R, Hagell P, Marras C, Martinez-Martin P, Mehta SH, Odin P, Chaudhuri KR, Weintraub D, Wilson B, Uitti RJ.

J Parkinsons Dis. 2017;7(3):533-543. doi: 10.3233/JPD-161055.

PMID:
28671140
9.

Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale.

Martinez-Martin P, Manuel Rojo-Abuin J, Rizos A, Rodriguez-Blazquez C, Trenkwalder C, Perkins L, Sauerbier A, Odin P, Antonini A, Chaudhuri KR; KPPS, EUROPAR and the IPMDS Non Motor PD Study Group.

NPJ Parkinsons Dis. 2017 Mar 15;3:8. doi: 10.1038/s41531-017-0009-1. eCollection 2017.

10.

An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.

Krüger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, Stefani A, Sensken SC, Parra JC, Onuk K, Yegin A, Antonini A.

Adv Ther. 2017 Jul;34(7):1741-1752. doi: 10.1007/s12325-017-0571-2. Epub 2017 Jun 19.

11.

Device-Aided Treatment Strategies in Advanced Parkinson's Disease.

Timpka J, Nitu B, Datieva V, Odin P, Antonini A.

Int Rev Neurobiol. 2017;132:453-474. doi: 10.1016/bs.irn.2017.03.001. Epub 2017 May 8.

PMID:
28554418
12.

Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease.

Fabbri M, Coelho M, Guedes LC, Rosa MM, Abreu D, Gonçalves N, Antonini A, Ferreira JJ.

Parkinsonism Relat Disord. 2017 Aug;41:113-117. doi: 10.1016/j.parkreldis.2017.05.003. Epub 2017 May 8.

PMID:
28528805
13.

Relationship between pain and motor and non-motor symptoms in Parkinson's disease.

Defazio G, Antonini A, Tinazzi M, Gigante AF, Pietracupa S, Pellicciari R, Bloise M, Bacchin R, Marcante A, Fabbrini G, Berardelli A.

Eur J Neurol. 2017 Jul;24(7):974-980. doi: 10.1111/ene.13323. Epub 2017 May 18.

PMID:
28516474
14.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13.

PMID:
28500752
15.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):955-971. doi: 10.1002/mds.27038. Epub 2017 May 13. Review.

PMID:
28500751
16.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

PMID:
28467028
17.

The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease.

Picillo M, Palladino R, Barone P, Erro R, Colosimo C, Marconi R, Morgante L, Antonini A; PRIAMO Study Group.

Eur J Neurol. 2017 Jun;24(6):788-795. doi: 10.1111/ene.13290. Epub 2017 Apr 20.

PMID:
28425642
18.

Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.

Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, Volonté MA, Antonini A, Perani D.

Neuroimage Clin. 2017 Mar 27;14:734-740. doi: 10.1016/j.nicl.2017.03.011. eCollection 2017.

19.

Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.

Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM, Abreu D, Costa N, Godinho C, Antonini A, Ferreira JJ.

Parkinsonism Relat Disord. 2017 Jun;39:37-43. doi: 10.1016/j.parkreldis.2017.02.007. Epub 2017 Feb 7.

PMID:
28389156
20.

The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.

Lehericy S, Vaillancourt DE, Seppi K, Monchi O, Rektorova I, Antonini A, McKeown MJ, Masellis M, Berg D, Rowe JB, Lewis SJG, Williams-Gray CH, Tessitore A, Siebner HR; International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group.

Mov Disord. 2017 Apr;32(4):510-525. doi: 10.1002/mds.26968. Epub 2017 Mar 28. Review.

PMID:
28370449

Supplemental Content

Loading ...
Support Center